The Role of Biomarkers in Rare Diseases

Biomarkers are measurable indicators of biological processes, disease states, or responses to therapy. If a biomarker exists for a rare condition, such as lyso-Gb1 (sphingolipid) which is a biomarker for Gaucher disease, can transform the landscape of rare disease diagnosis and management. Their integration into clinical and research settings is particularly vital given the unique challenges posed by rare diseases.

Rare diseases are often characterised by diverse clinical presentations, limited natural history data, and small patient populations, making diagnosis and disease monitoring especially challenging. Traditional diagnostic approaches may be invasive, time-consuming, or inconclusive. Biomarkers offer a more objective, efficient, and sometimes less invasive means to:

• Facilitate early and accurate diagnosis: Biomarkers can help identify diseases earlier and more precisely, reducing the risk of misdiagnosis or delayed treatment.

• Stratify disease subtypes: Molecular signatures can distinguish between disease subtypes, which is crucial for personalised medicine and targeted therapies.

• Monitor disease progression: Dynamic biomarkers (such as gene expression, metabolites, or proteins) can track changes in disease status, enabling clinicians to adjust management strategies promptly.

• Assess treatment response: Response biomarkers provide early indications of therapeutic efficacy, allowing for timely modifications to treatment plans and avoiding unnecessary exposure to ineffective therapies.

The use of biomarkers is reshaping rare disease drug development. Given the small size and heterogeneity of rare disease populations, biomarkers can:

• Support regulatory approval: Surrogate biomarkers may serve as endpoints in clinical trials, supporting accelerated approval pathways for new therapies when traditional clinical endpoints are impractical.

• Enable precision medicine: By identifying patients most likely to benefit from a specific therapy, biomarkers improve trial efficiency and therapeutic outcomes.

• Shorten clinical trials: Biomarkers can provide early, quantifiable measures of treatment effect, reducing the time and number of participants needed for statistically meaningful results.

Case studies, such as the use of pharmacodynamic biomarkers in the development of therapies for ultra-rare diseases like CHAPLE disease, illustrate how biomarkers can demonstrate efficacy and safety in very small cohorts, supporting regulatory flexibility and faster patient access to new treatments.

Despite their promise, the development and application of biomarkers in rare diseases face several hurdles:

• Validation and standardization: Biomarker assays must be rigorously validated for accuracy, precision, sensitivity, and reproducibility across laboratories and settings.

• Small sample sizes: The rarity of these conditions often limits the availability of patient samples, complicating biomarker discovery and validation.

• Heterogeneity: Clinical and genetic variability within rare diseases can make it difficult to identify universal biomarkers, often necessitating the use of biomarker panels rather than single markers.

• Integration into clinical practice: Translating biomarker discoveries into routine clinical use requires collaboration among researchers, clinicians, regulatory agencies, and patient communities.

An obvious call to action is to improve the rare disease biomarkers so that diagnosis and disease monitoring can be enhanced.

References:

1. Bax BE. Biomarkers in Rare Diseases 2.0. Int J Mol Sci. 2022, 23; 9: 4582. doi: 10.3390/ijms23094582

2. Ferlini A, Scotton C, Novelli G. Biomarkers in rare diseases. Public Health Genomics. 2013, 16; 6: 313-21. doi: 10.1159/000355938

3. Tang S, Yuan K, Chen L. Molecular biomarkers, network biomarkers, and dynamic network biomarkers for diagnosis and prediction of rare diseases. Fundamental Research. 2022, 2; 6: 894-902

4. May, M. Rare-disease researchers pioneer a unique approach to clinical trials. Nat Med. 2023, 29; 1884–1886. https://doi.org/10.1038/s41591-023-02333-4

5. Scotton C and Ferlini A. Biomarkers in Rare Genetic Diseases. Role of Biomarkers in Medicine. InTech. 2016. Available at: http://dx.doi.org/10.5772/63354